Jeffrey S. Riesmeyer

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 642 citations

Medicine, Pharmacology, Pharmacotherapy +16

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)

Stephen D. Wiviott, Elliott M. Antman, C. Michael Gibson et al. · American Heart Journal · 2006 · 327 citations

Medicine, Cardiology, Pharmacology +17

The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

Jonathan M. Wilson, Amir Nikooienejad, Deborah A. Robins et al. · Diabetes Obesity and Metabolism · 2020 · 157 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease

Rishi Puri, Steven E. Nissen, Benoît J. Arsenault et al. · JAMA Cardiology · 2020 · 120 citations · Full text

Medicine, Cardiology, Pharmacology +17